Aldeyra Therapeutics Inc represents values of innovation, integrity, and patient-centricity in the field of biopharmaceuticals. With a strong corporate philosophy, the company is committed to advancing novel therapies to address unmet medical needs. Aldeyra Therapeutics Inc offers innovative solutions that aim to improve patients' lives, leveraging cutting-edge scientific research and a dedicated team of professionals. Through their comprehensive approach, the company strives to develop transformative treatments and make a positive impact in the healthcare industry. The core values of Aldeyra Therapeutics Inc drive its mission to deliver effective and safe therapeutic options for patients worldwide.

Aldeyra Therapeutics Inc is primarily present in the United States.

Aldeyra Therapeutics Inc., a leading biotechnology company, has achieved several significant milestones. The company has made substantial progress in the development of novel therapies, particularly in the field of inflammation and immune-mediated diseases. Aldeyra Therapeutics Inc. successfully conducted pivotal clinical trials for their product candidates, demonstrating positive outcomes and proving their potential efficacy. In addition, they have secured valuable partnerships and collaborations with renowned pharmaceutical organizations, further validating their innovative approach. These achievements solidify Aldeyra Therapeutics Inc.'s position as a promising player in the biotech industry, dedicated to improving patients' lives through groundbreaking advancements.

Aldeyra Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of innovative therapeutic products for immune-mediated diseases. Founded in 2004, Aldeyra initially focused on research and development in the field of inflammation and cancer. Over the years, the company has shifted its focus towards developing novel treatments for conditions such as dry eye disease, allergic conjunctivitis, and Sjögren-Larsson Syndrome. Utilizing their proprietary platform, Aldeyra Therapeutics combines scientific expertise with cutting-edge technology to create potential breakthroughs in disease management. With a strong commitment to improving patient outcomes, Aldeyra Therapeutics Inc. continues to advance its pipeline of therapeutic candidates through rigorous research and clinical trials.

Aldeyra Therapeutics Inc faces competition from various companies in the market. Some of its main competitors include Allergan plc, Novartis International AG, and Johnson & Johnson. These companies also operate in the pharmaceutical industry, focusing on developing and marketing therapeutics for various medical conditions. Aldeyra Therapeutics Inc competes with them in terms of research and development, product pipeline, market presence, and commercialization strategies. By constantly innovating and offering unique solutions, Aldeyra Therapeutics Inc aims to stand out and differentiate itself from its competitors in the market.

Aldeyra Therapeutics Inc is primarily active in the pharmaceutical industry.

The business model of Aldeyra Therapeutics Inc focuses on developing and commercializing innovative therapies for the treatment of immune-mediated diseases. Aldeyra Therapeutics utilizes its expertise in the field of inflammation and immune modulation to develop novel therapies that target diseases with high unmet medical needs. The company's research and development efforts aim to advance its pipeline of potential drug candidates, with a particular focus on diseases impacting the eye and skin. By leveraging its proprietary technology platform and strategic collaborations, Aldeyra Therapeutics aims to bring effective treatments to patients suffering from various immune-mediated diseases.

مُعامل القيمة السوقية إلى الأرباح لـ Aldeyra Therapeutics هو ؜-٧٫٦٦.

مُعامِل القيمة إلى المبيعات Aldeyra Therapeutics هو ١٠٫٧٥.

نقاط جودة AlleAktien لـ Aldeyra Therapeutics هي 4/10.

المتوقعة Aldeyra Therapeutics الإيرادات هي ٢٩٫٠٠ مليون. USD.

صافي الربح المتوقعة Aldeyra Therapeutics هو ؜-٤٠٫٦٩ مليون. USD.

Aldeyra Therapeutics Inc is an American biopharmaceutical company specializing in the development of therapies for the treatment of eye diseases and inflammatory diseases. The company's business model is focused on developing and marketing innovative therapies based on the latest scientific knowledge and technologies. The company invests in research and development of innovative therapeutic approaches, commercialization of these therapies through sales activities and marketing campaigns, and acquisitions or licensing of other companies. Aldeyra Therapeutics' product portfolio currently includes several drug candidates, such as ADX-2191, ADX-1612, ADX-629, and ADX-103, with a high degree of innovation intended for the treatment of various diseases such as acute eye inflammation (conjunctivitis), neuroinflammatory diseases, and orphan diseases (rare diseases). One example is ADX-2191, a medication to be used in the treatment of allergic reactions in the eye. The company also forms targeted partnerships with other companies to develop new drug candidates, such as its collaboration with Elanco, a global leader in animal health, to develop ADX-2191 for the treatment of allergic conjunctivitis in animals. The company's products are marketed through business partners, distribution strategies, and collaborations with healthcare professionals and medical societies. Aldeyra Therapeutics prioritizes complying with the highest quality and ethical standards in the development and marketing of medications, ensuring scientific knowledge and treatment outcomes are communicated in accordance with applicable laws and regulations. Overall, Aldeyra Therapeutics' business model is based on the development of innovative therapeutic approaches for eye and inflammatory diseases, utilizing targeted research and development, strategic partnerships, and targeted sales activities, all while adhering to high quality standards and ethical principles.

يوزع Aldeyra Therapeutics أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Aldeyra Therapeutics في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـAldeyra Therapeutics هو US01438T1060.

رمز WKN لـ Aldeyra Therapeutics هو A111X8.

الرمز المُختصر لـ Aldeyra Therapeutics هو ALDX.

خلال آخر 12 شهراً، دفعت Aldeyra Therapeutics توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Aldeyra Therapeutics خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Aldeyra Therapeutics هي .

Aldeyra Therapeutics يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Aldeyra Therapeutics دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Aldeyra Therapeutics يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Aldeyra Therapeutics المُعلن عنها في ٢‏/١٠‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢‏/١٠‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢‏/١٠‏/٢٠٢٤.

في العام 2023، وزعت Aldeyra Therapeutics 0 USD كأرباح أسهم.

يتم توزيع أرباح Aldeyra Therapeutics بالعملة USD.